Celldex Therapeutics CLDX

$29.89 +0.23 (0.78%)

Valuation

Market cap
2,329,200,000
Revenue TTM
$1,550,000
Net income TTM
$-258,760,000
PE ratio
0.00
Forward PE
—
Profit margin
-16,694.19%
Debt to equity
0.00

Trading

Volume
918,800
Avg volume
1,454,260
Day's range
$29.47 – $30.39
Shares out
78,530,000
Stochastic %K
72%
Beta
0.90
Analysts
Strong Sell
Price target
$63.28

Price

Company profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159),...

Show more

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 200 7500
Website
https://www.celldex.com
Address
Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

Latest news

Stocktwits

Merlintrader Oct 27, 5:29 AM
$CLDX finished Monday at $29.50, below both the 50-day SMA ($34.97) and the 200-day ($32.34), in the lower part of its 20-day range ($27.47-$32.88). Daily RSI 42. $SPY $XBI Bull and bear scenarios, support/resistance and trendlines on the interactive JC Just Charts page: https://justcharts.merlintrader.com/#CLDX Not investment advice.
0 replies
Unburdened Oct 20, 5:28 PM
$CLDX Nice rally the last few days. Going up with rally in Biotechs??
0 replies
Steve1545 Oct 20, 2:47 PM
$CLDX
1 replies
lucabrix Oct 19, 7:10 PM
$CLDX Reply!!
0 replies
Steve1545 Oct 16, 11:18 PM
$CLDX Oct. calls expired worthless. 1 month til the Nov. ones do too. Then might see some upward momentum
1 replies
lucabrix Oct 8, 2:56 PM
$CLDX Celldex Therapeutics: FMR reports 10.7% stake FMR LLC reports sole voting power over 8,396,651 shares, while reporting person Abigail P. Johnson reports none.
0 replies
lucabrix Oct 6, 7:15 PM
$CLDX Celldex Therapeutics shares are under heavy pressure as traders focus on fresh safety worries tied to its lead drug, barzolvolimab. While the Phase 3 trial in chronic spontaneous urticaria hit its main goals, reports of two life-threatening anaphylaxis cases, a long regulatory path stretching into 2027, and a classic “sell the news” reaction have combined to overshadow the efficacy win and weigh on the stock. The setback comes even as the strong Phase 3 data reinforce the drug’s potential and underscore the value of Celldex’s antibody-focused pipeline, which could support the company’s long-term prospects if it successfully navigates regulators and competition.
1 replies
Quantumup Oct 5, 7:24 PM
B | RILEY (a/o 10/1) reiterated $CUE Buy-$83 after its KOL event (n=2). $CLDX $RHHBY - NVS SNY - REGN EVMN SPRY AZN IFRX NSRGY DBVT AMGN BMY MRK NKTR COYA Here's what B | RILEY said in its note: https://x.com/Quantumup1/status/2107189864626339938?s=20
1 replies